Serum Clusterin Level Could Reflect the Current Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices. Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item He...
Saved in:
Published in | Yonsei medical journal Vol. 62; no. 11; pp. 1016 - 1022 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Yonsei University College of Medicine
01.11.2021
연세대학교의과대학 |
Subjects | |
Online Access | Get full text |
ISSN | 0513-5796 1976-2437 1976-2437 |
DOI | 10.3349/ymj.2021.62.11.1016 |
Cover
Abstract | We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices.
Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV.
The median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 µg/mL, patients with serum clusterin level ≤130.45 µg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 µg/mL vs. 230.5 µg/mL).
Serum clusterin levels could reflect the current disease activity in patients with AAV. |
---|---|
AbstractList | We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices.PURPOSEWe investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices.Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV.MATERIALS AND METHODSFifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV.The median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 µg/mL, patients with serum clusterin level ≤130.45 µg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 µg/mL vs. 230.5 µg/mL).RESULTSThe median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 µg/mL, patients with serum clusterin level ≤130.45 µg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 µg/mL vs. 230.5 µg/mL).Serum clusterin levels could reflect the current disease activity in patients with AAV.CONCLUSIONSerum clusterin levels could reflect the current disease activity in patients with AAV. We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices. Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV. The median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 µg/mL, patients with serum clusterin level ≤130.45 µg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 µg/mL vs. 230.5 µg/mL). Serum clusterin levels could reflect the current disease activity in patients with AAV. Purpose: We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific indices. Materials and Methods: Fifty-seven patients with AAV and 40 healthy controls were included in this study. AAV-specific indices included the Short-Form 36-Item Health Survey Physical and Mental Component Summaries (SF-36 PCS and MCS) scores, Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and vasculitis damage index. Clinical and laboratory data and AAV-specific indices were obtained at blood collection. The highest tertile of BVAS (≥16) was defined as high activity of AAV. Results: The median age of AAV patients was 64.0 years and 19 patients were male. SF-36 PCS score (r=0.328), SF-36 MCS score (r=0.289), BVAS (r=-0.404), erythrocyte sedimentation rate (r=-0.336), and C-reactive protein levels (r=-0.421) were significantly correlated with serum clusterin levels. In the multivariable linear regression analysis using AAV-specific indices and serum clusterin levels, both FFS (β=0.412) and serum clusterin levels (β=-0.250) were significantly associated with BVAS. When the optimal serum clusterin cut-off level for high activity of AAV was identified as 130.45 μg/mL, patients with serum clusterin level ≤130.45μg/mL had a significantly higher risk for high activity of AAV than did those without (relative risk 7.194). Patients with AAV exhibited significantly lower serum clusterin levels than did healthy controls (168.2 μg/mL vs. 230.5 μg/mL). Conclusion: Serum clusterin levels could reflect the current disease activity in patients with AAV. KCI Citation Count: 0 |
Author | Yoon, Taejun Pyo, Jung Yoon Lee, Sang-Won Song, Jason Jungsik Ahn, Sung Soo Park, Yong-Beom |
AuthorAffiliation | 1 Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea 3 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea 2 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea |
AuthorAffiliation_xml | – name: 3 Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea – name: 1 Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea – name: 2 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Taejun orcidid: 0000-0003-2147-3555 surname: Yoon fullname: Yoon, Taejun organization: Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Korea – sequence: 2 givenname: Sung Soo orcidid: 0000-0002-9002-9880 surname: Ahn fullname: Ahn, Sung Soo organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 3 givenname: Jung Yoon orcidid: 0000-0002-1866-6885 surname: Pyo fullname: Pyo, Jung Yoon organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 4 givenname: Jason Jungsik orcidid: 0000-0003-0662-7704 surname: Song fullname: Song, Jason Jungsik organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea – sequence: 5 givenname: Yong-Beom orcidid: 0000-0003-4695-8620 surname: Park fullname: Park, Yong-Beom organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea – sequence: 6 givenname: Sang-Won orcidid: 0000-0002-8038-3341 surname: Lee fullname: Lee, Sang-Won organization: Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea., Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34672135$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002766533$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9kk9v1DAQxS1URLeFT4CEcoRDgv8ksX1BiqJCK62EVApXK3EmrFsnXmxnpXx7kt0WFQ6c5jDv955G8y7Q2ehGQOgtwRljufw4D_cZxZRkJc0IyQgm5Qu0IZKXKc0ZP0MbXBCWFlyW5-gihHuMKSeYvkLnLC85JazYoOkb-GlIajuFCN6MyRYOYJPaTbZLbqG3oGMSd5DUk_cwxqTS0RxMnBPXJ9UYzQhT9G6_Mws0R7e3TRiMPq5a181pFYLTponQJT-aoCdrogmv0cu-sQHePM5L9P3z1V19nW6_frmpq22qcyZj2grNO01byHvBRcEAuq4AzWXbEip4KQinLSnannadhFKKnErgjHNMGlIIwi7Rh5Pv6Hv1oI1yjTnOn049eFXd3t0oKTgtMV60n07a_dQO0OnlWN9YtfdmaPx8JP_ejGa3-ByUKHKa89Xg_aOBd78mCFENJmiwthnBTUHRQuRcSoHLRfruedafkKe_LAJ5EmjvQvDQK21iE41bo41VBKu1A2rpgFo7oEqqCFFrBxaW_cM-2f-P-g15prgJ |
CitedBy_id | crossref_primary_10_3389_fimmu_2023_1103097 crossref_primary_10_1002_jcla_24543 crossref_primary_10_4078_jrd_2022_0002 |
Cites_doi | 10.4049/jimmunol.177.9.6471 10.1136/ard.2006.054593 10.1136/ard.2008.101279 10.1620/tjem.203.189 10.2174/138945006777435317 10.2147/CMAR.S196273 10.1016/S0065-230X(09)04008-1 10.1002/art.37715 10.1097/MD.0b013e318205a4c6 10.1681/ASN.V351172 10.3349/ymj.2019.60.8.705 10.1007/s11926-012-0291-1 10.1016/j.bone.2018.02.018 10.1046/j.1365-2567.2003.01608.x 10.1016/j.biopha.2020.111174 10.1681/ASN.2016111179 10.1681/ASN.2016060690 10.1038/nrneph.2017.37 10.1136/annrheumdis-2012-201981 10.1111/imcb.12405 10.1038/nrrheum.2014.103 10.1056/NEJMoa0909905 |
ContentType | Journal Article |
Copyright | Copyright: Yonsei University College of Medicine 2021. Copyright: Yonsei University College of Medicine 2021 2021 Yonsei University College of Medicine |
Copyright_xml | – notice: Copyright: Yonsei University College of Medicine 2021. – notice: Copyright: Yonsei University College of Medicine 2021 2021 Yonsei University College of Medicine |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.3349/ymj.2021.62.11.1016 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1976-2437 |
EndPage | 1022 |
ExternalDocumentID | oai_kci_go_kr_ARTI_9872600 PMC8542470 34672135 10_3349_ymj_2021_62_11_1016 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Yonsei University College of Medicine grantid: 6-2019-0184 – fundername: Korea Health Industry Development Institute grantid: HI14C1324 – fundername: ; grantid: HI14C1324 – fundername: ; grantid: 6-2019-0184 |
GroupedDBID | --- .55 .GJ 123 29R 2WC 36B 5-W 53G 5RE 8JR 8XY 9ZL AAYXX ACYCR ADBBV ADRAZ AEGXH AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION CS3 DIK DU5 E3Z EBD EF. EMB EMOBN F5P GROUPED_DOAJ GX1 HYE KQ8 L7B M48 MK0 O5R O5S OK1 OVT P2P PGMZT RNS RPM SV3 TR2 X7M XSB ZGI ZXP CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c439t-b8c7dc2be4f87853eedd5ec79bb128768172b15bf2dd9e698429e737701a15813 |
IEDL.DBID | M48 |
ISSN | 0513-5796 1976-2437 |
IngestDate | Sun Mar 09 07:52:46 EDT 2025 Thu Aug 21 14:11:13 EDT 2025 Fri Jul 11 09:16:50 EDT 2025 Thu Apr 03 07:07:32 EDT 2025 Thu Apr 24 23:06:44 EDT 2025 Tue Jul 01 04:03:23 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | current activity antineutrophil cytoplasmic antibody vasculitis Clusterin |
Language | English |
License | Copyright: Yonsei University College of Medicine 2021. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c439t-b8c7dc2be4f87853eedd5ec79bb128768172b15bf2dd9e698429e737701a15813 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Taejun Yoon and Sung Soo Ahn contributed equally to this work. https://www.eymj.org/DOIx.php?id=10.3349/ymj.2021.62.11.1016 |
ORCID | 0000-0002-1866-6885 0000-0003-0662-7704 0000-0003-4695-8620 0000-0002-9002-9880 0000-0002-8038-3341 0000-0003-2147-3555 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3349/ymj.2021.62.11.1016 |
PMID | 34672135 |
PQID | 2584799806 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9872600 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8542470 proquest_miscellaneous_2584799806 pubmed_primary_34672135 crossref_citationtrail_10_3349_ymj_2021_62_11_1016 crossref_primary_10_3349_ymj_2021_62_11_1016 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-11-01 |
PublicationDateYYYYMMDD | 2021-11-01 |
PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Yonsei medical journal |
PublicationTitleAlternate | Yonsei Med J |
PublicationYear | 2021 |
Publisher | Yonsei University College of Medicine 연세대학교의과대학 |
Publisher_xml | – name: Yonsei University College of Medicine – name: 연세대학교의과대학 |
References | Mukhtyar (10.3349/ymj.2021.62.11.1016_ref11) 2009; 68 Peng (10.3349/ymj.2021.62.11.1016_ref15) 2019; 11 Rodríguez-Rivera (10.3349/ymj.2021.62.11.1016_ref1) 2021; 134 Jennette (10.3349/ymj.2021.62.11.1016_ref7) 2014; 10 Watts (10.3349/ymj.2021.62.11.1016_ref6) 2007; 66 Abdallah (10.3349/ymj.2021.62.11.1016_ref14) 2018; 110 Stone (10.3349/ymj.2021.62.11.1016_ref20) 2010; 363 Choi (10.3349/ymj.2021.62.11.1016_ref8) 2017; 28 Bhamra (10.3349/ymj.2021.62.11.1016_ref13) 2012; 14 Park (10.3349/ymj.2021.62.11.1016_ref23) 2006; 7 Newkirk (10.3349/ymj.2021.62.11.1016_ref4) 1999; 26 Choi (10.3349/ymj.2021.62.11.1016_ref21) 2019; 60 Monach (10.3349/ymj.2021.62.11.1016_ref9) 2013; 72 Han (10.3349/ymj.2021.62.11.1016_ref10) 2004; 203 Jayne (10.3349/ymj.2021.62.11.1016_ref22) 2017; 28 Jennette (10.3349/ymj.2021.62.11.1016_ref5) 2013; 65 Agrawal (10.3349/ymj.2021.62.11.1016_ref16) 2003; 108 Correa-Rotter (10.3349/ymj.2021.62.11.1016_ref18) 1992; 3 Weng (10.3349/ymj.2021.62.11.1016_ref17) 2021; 99 Chen (10.3349/ymj.2021.62.11.1016_ref19) 2017; 13 Devauchelle (10.3349/ymj.2021.62.11.1016_ref3) 2006; 177 Guillevin (10.3349/ymj.2021.62.11.1016_ref12) 2011; 90 Falgarone (10.3349/ymj.2021.62.11.1016_ref2) 2009; 104 |
References_xml | – volume: 177 start-page: 6471 year: 2006 ident: 10.3349/ymj.2021.62.11.1016_ref3 publication-title: J Immunol doi: 10.4049/jimmunol.177.9.6471 – volume: 66 start-page: 222 year: 2007 ident: 10.3349/ymj.2021.62.11.1016_ref6 publication-title: Ann Rheum Dis doi: 10.1136/ard.2006.054593 – volume: 68 start-page: 1827 year: 2009 ident: 10.3349/ymj.2021.62.11.1016_ref11 publication-title: Ann Rheum Dis doi: 10.1136/ard.2008.101279 – volume: 203 start-page: 189 year: 2004 ident: 10.3349/ymj.2021.62.11.1016_ref10 publication-title: Tohoku J Exp Med doi: 10.1620/tjem.203.189 – volume: 7 start-page: 661 year: 2006 ident: 10.3349/ymj.2021.62.11.1016_ref23 publication-title: Curr Drug Targets doi: 10.2174/138945006777435317 – volume: 11 start-page: 2405 year: 2019 ident: 10.3349/ymj.2021.62.11.1016_ref15 publication-title: Cancer Manag Res doi: 10.2147/CMAR.S196273 – volume: 104 start-page: 139 year: 2009 ident: 10.3349/ymj.2021.62.11.1016_ref2 publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(09)04008-1 – volume: 65 start-page: 1 year: 2013 ident: 10.3349/ymj.2021.62.11.1016_ref5 publication-title: Arthritis Rheum doi: 10.1002/art.37715 – volume: 90 start-page: 19 year: 2011 ident: 10.3349/ymj.2021.62.11.1016_ref12 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0b013e318205a4c6 – volume: 3 start-page: 1172 year: 1992 ident: 10.3349/ymj.2021.62.11.1016_ref18 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.V351172 – volume: 26 start-page: 597 year: 1999 ident: 10.3349/ymj.2021.62.11.1016_ref4 publication-title: J Rheumatol – volume: 60 start-page: 705 year: 2019 ident: 10.3349/ymj.2021.62.11.1016_ref21 publication-title: Yonsei Med J doi: 10.3349/ymj.2019.60.8.705 – volume: 14 start-page: 494 year: 2012 ident: 10.3349/ymj.2021.62.11.1016_ref13 publication-title: Curr Rheumatol Rep doi: 10.1007/s11926-012-0291-1 – volume: 110 start-page: 221 year: 2018 ident: 10.3349/ymj.2021.62.11.1016_ref14 publication-title: Bone doi: 10.1016/j.bone.2018.02.018 – volume: 108 start-page: 539 year: 2003 ident: 10.3349/ymj.2021.62.11.1016_ref16 publication-title: Immunology doi: 10.1046/j.1365-2567.2003.01608.x – volume: 134 start-page: 111174 year: 2021 ident: 10.3349/ymj.2021.62.11.1016_ref1 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2020.111174 – volume: 28 start-page: 2756 year: 2017 ident: 10.3349/ymj.2021.62.11.1016_ref22 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2016111179 – volume: 28 start-page: 3191 year: 2017 ident: 10.3349/ymj.2021.62.11.1016_ref8 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2016060690 – volume: 13 start-page: 359 year: 2017 ident: 10.3349/ymj.2021.62.11.1016_ref19 publication-title: Nat Rev Nephrol doi: 10.1038/nrneph.2017.37 – volume: 72 start-page: 1342 year: 2013 ident: 10.3349/ymj.2021.62.11.1016_ref9 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-201981 – volume: 99 start-page: 274 year: 2021 ident: 10.3349/ymj.2021.62.11.1016_ref17 publication-title: Immunol Cell Biol doi: 10.1111/imcb.12405 – volume: 10 start-page: 463 year: 2014 ident: 10.3349/ymj.2021.62.11.1016_ref7 publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2014.103 – volume: 363 start-page: 221 year: 2010 ident: 10.3349/ymj.2021.62.11.1016_ref20 publication-title: N Engl J Med doi: 10.1056/NEJMoa0909905 |
SSID | ssj0027102 |
Score | 2.3132765 |
Snippet | We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)-specific... Purpose: We investigated whether serum clusterin levels could reflect the current antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1016 |
SubjectTerms | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies, Antineutrophil Cytoplasmic Blood Sedimentation Clusterin - blood Humans Male Middle Aged Original 의학일반 |
Title | Serum Clusterin Level Could Reflect the Current Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34672135 https://www.proquest.com/docview/2584799806 https://pubmed.ncbi.nlm.nih.gov/PMC8542470 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002766533 |
Volume | 62 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Yonsei Medical Journal, 2021, 62(11), , pp.1016-1022 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1db9MwFLXWISFeEOOzjFUG8UhG7SS28zChqmIaiPGAKOzNij-yhbVJlyUS_fe7N0kLRQOJl0RK7FjxtXPuia_PJeQ1E8J6J2wQMQeHcWKCFOcVONfWAV7i3kmMtvgsTmbRx7P4bIess6L2HXh9K7XDfFKzan7482r1Dib8ETLOMErerhY_gOhxdig4fAFaPjogdwCaBLKx00j9YmCsDUKEgRgGuAmzkyH620O2oGpQVNltXuifwZS_odPxA3K_dyvppBsHe2THFw_J3dN-4fwRaeCb0CzodN6gMEJe0E8YLESnmOCafvEZ_ryn4AvSXq-JTmyXVoKWGZ1gNgnf1FW5vMih0qoul-B0L3Lb3jKlWwVrM3tHv7XBraiV9JjMjt9_nZ4EfcaFwIJjUgdGWeksNz7KlAQgBwB1sbcyMQZwDJgJuDuGxSbjziVeJArQzMtQyjFLWaxY-ITsFmXhnxGa4goxV8om3EaGxyb1UEgYJ4xHCZwh4evO1baXI8esGHMNtAQtosEiGi2iBQee0saiDcmbTaVlp8bx7-KvwGr60uYaVbTxfF7qy0oDV_igEyVRnX9IXq6NqmFq4XpJWviyudYcl5CBjo7hQU87I29aDQFgOAvjIZFb5t8UwAa37xT5RSvfreKIR3L8_P_eZZ_cwyvdNsgXZLeuGn8A_lBtRmQQB99H7d-EUTvebwCf8Qjd |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+Clusterin+Level+Could+Reflect+the+Current+Activity+of+Antineutrophil+Cytoplasmic+Antibody-Associated+Vasculitis&rft.jtitle=Yonsei+medical+journal&rft.au=Yoon%2C+Taejun&rft.au=Ahn%2C+Sung+Soo&rft.au=Pyo%2C+Jung+Yoon&rft.au=Song%2C+Jason+Jungsik&rft.date=2021-11-01&rft.issn=0513-5796&rft.eissn=1976-2437&rft.volume=62&rft.issue=11&rft.spage=1016&rft_id=info:doi/10.3349%2Fymj.2021.62.11.1016&rft.externalDBID=n%2Fa&rft.externalDocID=10_3349_ymj_2021_62_11_1016 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon |